WARREN, N.J.--(BUSINESS WIRE)--The CYPHER® Sirolimus-eluting Coronary Stent reduced by more than half the rate of major adverse cardiac events (MACE) compared to the Taxus Stent in small coronary vessels according to data appearing this week in the Journal of the American College of Cardiology.
